Microneedle RNA Profiling for Psoriasis Treatment Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like psoriasis are costly and ineffective due to genetic variability among patients, requiring a trial-and-error approach, and there is a need for a more precise method to predict patient response to therapeutic drugs.
Innovation Solution
A microneedle device with a specific design and nucleic acid probes is used to extract RNA from the skin, allowing for high-throughput sequencing and gene expression analysis to predict the effectiveness of IL-17, IL-23, or TNFα-mediated treatments with a positive predictive value greater than 80%, using a trained algorithm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a single therapeutic is prescribed to treat autoimmune disease, then the treatment approach is simplified, but the effectiveness is reduced due to genetic variability requiring trial-and-error
Solution Approach 1:
The patent performs gene expression profiling and machine learning-based prediction before prescribing treatment, allowing the optimal therapeutic to be identified in advance rather than through trial-and-error. This preliminary diagnostic action enables direct prescription of the most effective treatment without simplification compromising effectiveness.
2Reliability
If trial-and-error methodology is used to determine effective therapeutic, then treatment effectiveness can be achieved, but the time required is increased substantially
Solution Approach 1:
The system performs comprehensive gene expression analysis and machine learning prediction before treatment initiation, determining therapeutic effectiveness in advance. This eliminates the months-long trial-and-error period by providing upfront prediction of which treatment will work, achieving both effectiveness and time efficiency.
Solution Approach 2:
The patent uses machine learning algorithms trained on gene expression data to provide feedback about predicted treatment response. This feedback mechanism allows clinicians to select the most effective treatment based on objective predictive data rather than guessing, dramatically reducing the time to effective treatment.
3Reliability
If multiple therapeutic trials are conducted to find effective treatment, then the correct treatment can be identified, but the cost is increased significantly
Solution Approach 1:
The patent performs a single comprehensive gene expression profiling and machine learning analysis before treatment selection, replacing multiple costly therapeutic trials with one upfront diagnostic investment. This preliminary action identifies the effective treatment beforehand, avoiding repeated medication costs and medical visits.
Solution Approach 2:
The machine learning-based predictive feedback provides objective data about treatment likelihood of success, enabling cost-effective selection of the first-line treatment. This feedback replaces expensive trial-and-error medication costs with a single diagnostic test and computational analysis.
4Ease of operation
If conventional microneedle device is used for RNA extraction, then skin sampling is achieved, but the structural support and extraction efficiency are insufficient
Solution Approach 1:
The patent uses a composite microneedle structure combining a support substrate material with a separate RNA-binding functional layer. This composite design provides both the mechanical strength needed for skin penetration and the chemical functionality for efficient RNA binding and extraction, overcoming the limitations of single-material microneedles.
Solution Approach 2:
The microneedle device is segmented into distinct functional components: a support substrate providing structural integrity and separate RNA-binding elements on the microneedle surfaces. This segmentation allows optimization of each component for its specific function, improving both penetration reliability and RNA extraction efficiency.
Data Source
AI summary
The present disclosure provides methods of treating psoriasis. The present disclosure provides methods of using a microneedle device in aid of treating a subject. The present disclosure also provides methods of treating a subject with psoriasis with a microneedle device. The present disclosure provides microneedle devices and kits for extracting biomarkers from a tissue. The present disclosure provides methods selecting a treatment for an autoimmune disease. The present disclosure also provides methods of nucleic acid analysis to prospectively predict a patient's response to a therapeutic.